L-glutamic acid diethylester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-glutamic acid diethylester
• 英文别名: 4-Amino-5-ethoxy-5-oxopentanoic acid
• 化学式: C₇H₁₃NO₄
• 分子量: 175.185
• InChiKey: SYQNQPHXKWWZFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(苄氧羰基)-L-谷氨酸 、 L-glutamic acid diethylester 在 三乙胺 、 亚磷酸三乙酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Z-Glu-Glu-OC2H5
  参考文献：
  名称：

  Mitin,Yu.V.; Vlasov,P.G., Doklady Chemistry, 1968, vol. 179, p. 236 - 237

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS
  申请人：KANDULA Mahesh

  公开号：US20150111932A1

  公开（公告）日：2015-04-23

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurological degenerative disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and depression.

  该发明涉及公式I和公式II或其药学上可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。含有公式I或公式II化合物的有效量的药物组合物；以及用于治疗或预防神经退行性疾病的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗帕金森病（PD）、不安腿综合征（RLS）、集束性头痛、抑郁症、纤维肌痛、性功能障碍、肌萎缩侧索硬化症（ALS），又称路易·盖里格病和抑郁症。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：CELLIXBIO PRIVATE LIMITED

  公开号：US20150291590A1

  公开（公告）日：2015-10-15

  The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.

  该发明涉及公式I、公式II和公式III的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I、公式II或公式III化合物的有效量的药物组合物；以及用于治疗或预防代谢性疾病的方法可以制备成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂。这些组合物可用于治疗苯丙酮尿症、心血管疾病、自闭症、注意力缺陷多动障碍、高血压、内皮功能障碍和慢性肾脏疾病。
• N-transfer reagent and method for preparing the same and its application
  申请人：NATIONAL CHENG KUNG UNIVERSITY

  公开号：US11040939B1

  公开（公告）日：2021-06-22

  Provided are a novel N-transfer reagent and a method for preparing the same and its application. The N-transfer reagent is represented by the following Formula (I): The various novel N-transfer reagents of the present invention can be quickly prepared by employing different nitrobenzene precursors. The N-transfer reagents can directly convert a variety of amino compounds into diazo compounds under mild conditions. Particularly, the N-transfer reagents can facilitate the synthesis of the diazo compounds. The application of synthesizing diazo compounds of the present invention can greatly decrease the difficulty in operation, increase the safety during experiments, reduce the cost of production and the environmental pollution, and enhance the industrial value of diazo compounds.

  提供了一种新颖的N-转移试剂及其制备方法和应用。N-转移试剂由以下式（I）表示：本发明的各种新颖N-转移试剂可以通过采用不同的硝基苯前体快速制备。在温和条件下，N-转移试剂可以直接将各种氨基化合物转化为重氮化合物。特别地，N-转移试剂可以促进重氮化合物的合成。本发明用于合成重氮化合物的应用可以大大降低操作难度，增加实验安全性，减少生产成本和环境污染，提高重氮化合物的工业价值。
• Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors
  申请人：Jean Francois

  公开号：US20100168225A1

  公开（公告）日：2010-07-01

  Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G 1 is H or OH; G 2 is H, R′, or CO 2 R′; G 3 , G 4 and G 5 , are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH 2 , NHR′,NR′ 2 , CN, SH, SR′, SO 3 H, SO 3 R′, SO 2 R′, OSO 3 R′, and NO 2 ; and R′ is a one to four carbon alkyl group are provided. Uses of these compounds and methods of medical treatment involving these compounds for the treatment of hepatitis C are also provided.

  提供化学式5的化合物和化学式5的前药化合物，其中G1为H或OH；G2为H、R′或CO2R′；G3、G4和G5分别独立地选自以下组中的一种：H、R′、OH、OR′、F、Cl、Br、I、NH2、NHR′、NR′2、CN、SH、SR′、SO3H、SO3R′、SO2R′、OSO3R′和NO2；R′为一至四个碳的烷基。还提供了这些化合物的用途和涉及这些化合物的医学治疗方法，用于治疗丙型肝炎。
• PROCESS FOR PRODUCING CELLULOSE ACYLATE FILM
  申请人：Fuji Photo Film Co., Ltd.

  公开号：EP1437217A1

  公开（公告）日：2004-07-14

  A cellulose acylate film is produced by using a cellulose acylate solution and forming a film consisting of two or more layers by the co-casting method. The cellulose acylate to be used is selected so that the association molecular weight of cellulose acylate due to the static light scattering in the solution forming the outer layer becomes smaller than the association molecular weight of cellulose acylate due to the static light scattering in the solution forming the inner layer.

  使用丙烯酸纤维素溶液，通过共铸方法形成由两层或多层组成的薄膜，从而生产出丙烯酸纤维素薄膜。所使用的丙烯酸纤维素的选择应使形成外层的溶液中因静态光散射而产生的丙烯酸纤维素的结合分子量小于形成内层的溶液中因静态光散射而产生的丙烯酸纤维素的结合分子量。